Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 17 January 2026 - 19 January 2026

AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

AbbVie shares fell 1.1% to $214.35 after its blood cancer drug epcoritamab failed to show a clear overall-survival benefit in a late-stage trial. U.S. stock and bond markets were closed Monday for Martin Luther King Jr. Day. Investors are awaiting AbbVie’s Feb. 4 earnings for updated 2026 guidance.
19 January 2026
······
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
····
Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

COPENHAGEN, Jan 18, 2026, 21:16 CET — Market closed. Novo Nordisk A/S Class B shares (NOVOb.CO) surged 6.49% on Friday, closing at 388.9 Danish crowns after hitting a high of 391.3 crowns during the session. The stock is set to reopen Monday, with traders reacting to the latest Wegovy news. (Investing.com) Investors are weighing whether Novo’s once-daily Wegovy pill is gaining traction in the U.S. as the obesity drug market shifts toward a consumer-driven, cash-pay model. IQVIA data revealed 3,071 retail prescriptions filled within the first four days after its Jan. 5 launch. Novo described the “early signs” as positive
18 January 2026
·······
Merck stock (MRK) heads into a holiday pause as FDA fast-review program draws scrutiny

Merck stock (MRK) heads into a holiday pause as FDA fast-review program draws scrutiny

New York, Jan 18, 2026, 14:53 EST — Market closed. Merck & Company, Inc. shares closed Friday at $108.83, slipping 1.9%. U.S. markets will be shut Monday for Martin Luther King Jr. Day. (Yahoo Finance) Investors now have a few days to weigh a growing regulatory issue for major drug companies: just how much influence the FDA’s drive for quicker approvals should carry. The next regular trading session isn’t until Tuesday. Timelines are crucial for Merck. The stock’s trajectory still hinges largely on upcoming pipeline developments and the pace at which new drugs clear regulatory hurdles. Merck upgraded its forecast
18 January 2026
·····
Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab — what to watch next week

Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab — what to watch next week

Zurich, January 18, 2026, 20:45 CET — The market has closed. Novartis shares rose close to 1% on Friday after the Swiss pharma giant announced that U.S. regulators had granted a Breakthrough Therapy designation to ianalumab, its drug candidate for Sjögren’s disease. The stock finished at 115.60 Swiss francs on the SIX Swiss Exchange. (MarketWatch) The designation is important because it aims to accelerate development and review for drugs targeting serious illnesses when early clinical data indicate they might outperform existing treatments. It also often leads to more frequent FDA engagement and a quicker route toward submitting an application —
18 January 2026
····
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

New York, Jan 18, 2026, 11:03 EST — Market closed AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two other late-stage epcoritamab trials in 2026, including studies combining the drug with standard chemotherapy and Bristol Myers Squibb’s Revlimid. (Reuters) Why this matters now: AbbVie is hunting for fresh growth drivers as investors question the staying power of its lineup
18 January 2026
·······
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Copenhagen, Jan 18, 2026, 13:52 CET — Market closed. Shares of Novo Nordisk jumped 6.49% to 388.90 Danish crowns on Friday, marking their biggest daily gain in weeks. The surge came after new demand signals for its Wegovy obesity drug and a UK approval for a higher Wegovy dose brought the stock back into focus for investors. (MarketWatch) This stock move is significant as investors seek solid proof that Novo can expand Wegovy beyond injections and compete with Eli Lilly in the fiercely contested obesity drug market, a key growth battleground. Markets were closed over the weekend, so Monday will
18 January 2026
····
Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

New York, January 18, 2026, 06:30 EST — Market closed Pfizer Inc (PFE) shares slipped 0.93% to $25.65 on Friday. Reuters reported that some drugmakers harbor quiet concerns over a White House-backed fast FDA review program, fearing it could increase legal risks if a rushed process overlooks safety problems. Pfizer has reportedly considered joining the initiative, according to Reuters. (Investing.com) U.S. stock markets will be closed Monday in observance of Martin Luther King Jr. Day, shortening the trading week and shifting the next session to Tuesday. This heightens the impact of any policy news released before the opening bell. (New
18 January 2026
·····
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Copenhagen, January 17, 2026, 21:05 CET — The market has closed. Shares of Novo Nordisk A/S Class B jumped 6.5%, finishing Friday at 388.9 Danish crowns. The late-week surge put the stock in a stronger position ahead of Monday’s market open. Trading volume hit roughly 13.9 million shares amid a session that shifted alongside the news cycle. (Investing.com) This move is crucial since investors need clear evidence that Novo’s obesity franchise can sustain growth amid rising competition. Early prescription figures are now seen as indicators of pricing strength, market access, and the pace at which demand expands beyond weekly injections.
17 January 2026
·····
Roche stock price in focus: Goldman flips to neutral as ROG heads into Jan. 29 results

Roche stock price in focus: Goldman flips to neutral as ROG heads into Jan. 29 results

Zurich, Jan 17, 2026, 17:40 CET — The market has closed. Roche Holding shares (ROG.S) closed Friday 0.93% higher at 348.90 Swiss francs on the Swiss Exchange, a gain of 3.20 francs from Thursday’s finish. Swiss markets remain closed Saturday. (MarketScreener) The shift is significant as broker upgrades begin to reflect a rally that’s driven Roche’s valuation to tighter margins. With markets closed, investors face Monday assessing if Friday’s upgrades signal a genuine change in Wall Street’s view of Roche’s 2026 pipeline outlook. Goldman Sachs upgraded Roche to neutral from sell and raised its price target to 365 Swiss francs
17 January 2026
·····
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

New York, Jan 17, 2026, 10:03 ET — Market closed. Eli Lilly shares ended Friday up 0.5%, closing at $1,038.40. Investors enter the week anticipating a delayed U.S. regulatory verdict on the drugmaker’s experimental obesity medication. The key issue now is timing. A postponed verdict on Lilly’s oral weight-loss drug comes amid a rapidly evolving race, where pills aim to expand the market beyond injectable treatments. This matters because the company’s upcoming catalysts come in quick succession, and with the U.S. market reopening Tuesday after a holiday, the stock has limited time to absorb new developments before the next wave
17 January 2026
·····
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

New York, January 17, 2026, 07:32 EST — Market closed. Shares of Pfizer Inc (PFE) closed Friday down 0.9% at $25.65. Investors wrestled with a jumble of policy updates, regulatory filings, and a biotech IPO that dragged Pfizer’s name back into the paperwork spotlight. The next real hurdle for the stock arrives Tuesday. U.S. markets shut Monday for Martin Luther King Jr. Day, tightening the news flow and often making the session after the holiday a bit jittery. (NYSE) Pfizer CEO Albert Bourla expressed he was “seriously frustrated” following U.S. Health Secretary Robert F. Kennedy Jr.’s decision to roll back
17 January 2026
·····
1 … 11 12 13 14 15 … 56

Stock Market Today

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

7 February 2026
Rio Tinto’s U.S. shares closed up 2.5% at $93.37 Friday after the company ruled out a merger with Glencore, triggering a six-month “no-bid” lockout under UK takeover rules. Both companies cited disagreements over valuation. Attention now turns to Rio’s Feb. 19 results and iron ore prices, which fell below $100 a tonne amid weak Chinese demand.
iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Sembcorp shares closed at S$6.05 on Friday, down 0.33%, as Singapore’s STI dropped 0.8%. Shareholders approved the A$6.5 billion Alinta Energy takeover on Jan 30, but the deal still faces regulatory and closing conditions. Sembcorp will release FY2025 results on Feb 25 before market open. Trading volume reached about 4.3 million shares.
Go toTop